Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization

Authors:
  • GWGiora Weisz
    Giora Weisz
  • KPKristi Prather
    Kristi Prather
  • SJStefan James
    Stefan James
  • DMDaniel B. Mark
    Daniel B. Mark
  • KAKevin J. Anstrom
    Kevin J. Anstrom
  • LDLinda Davidson-Ray
    Linda Davidson-Ray
  • AWAdam Witkowski
    Adam Witkowski
  • AMAngel J. Mulkay
    Angel J. Mulkay
  • AOAnna Osmukhina
    Anna Osmukhina
  • RFRamin Farzaneh-Far
    Ramin Farzaneh-Far
  • OBOri Ben-Yehuda
    Ori Ben-Yehuda

Abstract
Background—: Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI patients. Methods and Results—: In RIVER-PCI, 2604 patients with a history of chronic angina who had ICR post-PCI were randomized 1:1 to oral ranolazine versus placebo; QOL analyses included 2389 randomized subjects. Angina and QOL questionnaires were collected at baseline and months 1, 6, and 12. Ranolazine patients were more likely than placebo to discontinue study drug by month 6 (20.4% versus 14.1%, P P P =0.01) to month 1 (86.6±18.1 versus 85.8±18.5, P =0.27) and month 12 (88.4±17.8 versus 88.5±17.8, P =0.94). SAQ angina frequency repeated measures did not differ in adjusted analysis between groups post baseline (mean difference 1.0; 95% CI -0.2, 2.2; P =0.11). Improvement in SAQ angina frequency was observed with ranolazine at month 6 among diabetics (mean difference 3.3; 95% CI 0.6, 6.1; P =0.02) and those with more angina (baseline SAQ angina frequency ≤60; mean difference 3.4; 95% CI 0.6, 6.2; P =0.02), but was not maintained at month 12. Conclusions—: Despite ICR following PCI, there was no incremental benefit in angina or QOL measures by adding ranolazine in this angiographically-identified population. These measures markedly improved within 1 month of PCI and persisted up to 1 year in both treatment arms. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01442038.

This publication has 38 references indexed in Scilit: